文献速递妇科肿瘤

H3K4me1介导的表观基因组预置塑造卵巢癌化疗耐药状态

H3K4me1-Mediated Epigenomic Priming of Chemoresistant Tumor States in Ovarian Cancer.
PubMed 文献 · Cancer Discov · 2026-10-19

该研究对16例高级别浆液性卵巢癌患者的纵向冷冻活检样本进行多模态单核测序,分析转录程序与组蛋白修饰。发现化疗前肿瘤细胞已存在表观遗传预置状态,耐药相关程序(TNFα相关和EMT相关)在治疗前即富集H3K4me1,且基线肿瘤组成与生存相关。

要点

  • 化疗前HGSOC肿瘤细胞已存在表观遗传预置的耐药状态。
  • H3K4me1在治疗前富集于TNFα和EMT相关耐药程序。
  • 基线肿瘤组成与患者生存相关,成纤维细胞重塑伴随恶性适应。

核心结论

  • HGSOC化疗耐药进化由治疗前存在的表观遗传预置肿瘤细胞状态所预示。

研究设计与样本

  • 研究采用多模态单核方法,对16例HGSOC患者的纵向冷冻活检样本进行转录程序和组蛋白修饰分析。

主要发现

  • 肿瘤由有限的功能状态组成,化疗下可重复演化:增殖和IFN反应状态耗竭,TNFα相关和EMT相关程序持续或扩增。
  • 染色质谱显示耐药程序在治疗前广泛富集H3K4me1。
  • 基线肿瘤组成与生存相关,成纤维细胞重塑伴随恶性适应。

临床怎么用

  • 该多模态单核方法可在临床兼容条件下从活检样本中预判耐药,为提前干预提供框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Non-genetic intratumor heterogeneity underlies therapeutic failure in cancer, yet how resistant tumor states are encoded in patients remains unclear. In this study, we show that chemoresistant evolution in high-grade serous ovarian cancer (HGSOC) is prefigured by epigenetically primed tumor cell states present before therapy. Using multimodal single-nucleus approaches, we profile transcriptional programs and histone modifications from longitudinal frozen biopsies of 16 patients with HGSOC. Tumors comprise a limited set of functional states that evolve reproducibly under chemotherapy: proliferative and IFN-responsive states are depleted, whereas TNFα-associated and epithelial-mesenchymal transition-associated programs persist or expand. Chromatin profiling reveals that these resistant programs are broadly enriched for histone H3 lysine 4 monomethylation (H3K4me1) prior to treatment, indicating that features of resistance are epigenomically primed. Baseline tumor composition is associated with survival, and fibroblast remodeling accompanies malignant adaptation. Together, these findings identify epigenomic priming as a feature of chemoresistant tumor cell states and provide a scalable framework for anticipating resistance from biopsies. SIGNIFICANCE: Using a clinically compatible multimodal single-nucleus approach, the authors show that chemoresistant evolution in HGSOC is prefigured by epigenetically primed tumor cell states present before therapy.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Landais Y, Bertorello J, Puerto MP, et al. H3K4me1-Mediated Epigenomic Priming of Chemoresistant Tumor States in Ovarian Cancer. Cancer Discov. 2026. PMID: 42895184. doi:10.1158/2159-8290.CD-26-0180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。